Shares of NRx Pharmaceuticals, Inc. (NRXP) are down over 32% at $2.40 in premarket trading today, following the release of results from a phase IIb/III trial of NRX-101 in treatment of suicidal bipolar depression.
In the study, NRX-101 demonstrated a 33% reduction in sustained remission in suicidality (not statistically significant at this sample size) and 75% advantage in relief from Akathisia relative to Lurasidone, according to the company.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.